Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025 GlobeNewswire November 03, 2025 RADNOR, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), […]

Blaqclouds, Inc. Announces the November 6, 2025 Official Launch of ApolloID — The Web3 Identity Layer of the ZEUS Ecosystem GlobeNewswire November 03, 2025 ROBESONIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) — Blaqclouds, Inc. (OTC: BCDS), a leading innovator in decentralized Web3 infrastructure and blockchain technology, proudly announces that on November 6, 2025, at 5:00

Apollo Funds Complete Acquisition of Stream Data Centers SDC Positioned to Accelerate Development Across Multi-Gigawatt Hyperscale Pipeline with Apollo Funds' Capital and Strategic Support GlobeNewswire November 03, 2025 NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Apollo-managed funds (the “Apollo Funds”) have completed the previously announced acquisition of a

Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results GlobeNewswire November 03, 2025 SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced

LM Funding America Announces $1.5 Million Share Repurchase Program GlobeNewswire November 03, 2025 TAMPA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury and mining company, today announced that its Board of Directors has authorized a share repurchase program to buy up to

Board of Advisors, LLC (BA) Celebrates a Decade of Innovation with Q4 National Summit for High-Growth Entrepreneurs and Investors in Dallas, Nov.3-7 GlobeNewswire November 03, 2025 -2025 is BA's most significant year yet with new locations and an expanding set of programs to facilitate deal flow, high-power networking, and strategic support for company growth- DALLAS,

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance GlobeNewswire November 03, 2025 Initial funding of $25 million from the first of four tranches Facility strengthens Kyverna's financial flexibility, further supporting advancement of its late-stage indications in generalized myasthenia gravis (gMG) and stiff person syndrome (SPS), while also accelerating pre-launch activities

Immutep Receives A$4.6 million R&D Tax Incentive from French Government GlobeNewswire November 03, 2025 Media Release SYDNEY, AUSTRALIA, Nov. 03, 2025 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, is pleased to announce it has received a EUR2,588,954 (~ A$4,567,769 )

Inseego Strengthens Board of Directors with Experienced Operational Leaders in Carrier, AI, and SaaS Nabil Bukhari and Stephen Bye bring decades of experience to Inseego's Board of Directors as it continues to invest to drive growth and profitability GlobeNewswire November 03, 2025 SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Inseego Corp. (Nasdaq: INSG), a

Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors Life Bio adds accomplished biotech leader to its Board as the company prepares for an early 2026 initiation of human trials GlobeNewswire November 03, 2025 BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) — Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation therapies